{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:52Z","timestamp":1794009112293,"version":"4.8.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We reported a 72-year-old man who was diagnosed with squamous lung cancer and received 2 cycles of <jats:sup>177<\/jats:sup>Lu-FAP-2286 treatment. Radiological remission was observed on follow-up FAP imaging 7 months later with squamous cell carcinoma antigen decreased to normal level. No other abnormality monitored by routine laboratory examination was noted.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005489","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:01:01Z","timestamp":1730815261000},"page":"103-104","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["177Lu-FAP-2286 Therapy in a Case of Squamous Lung Cancer"],"prefix":"10.1097","volume":"50","author":[{"given":"Linwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Chen","sequence":"additional","affiliation":[{"name":"Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"bib1-20241203","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib2-20241203","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00259-024-06635-8","article-title":"[68Ga]Ga-FAP-2286, a novel promising theragnostic approach for PET\/CT imaging in patients with various type of metastatic cancers","volume":"51","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20241203","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00259-023-06272-7","article-title":"Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides","volume":"50","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20241203","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20241203","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib6-20241203","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/RLU.0000000000004865","article-title":"177Lu-FAP-2286 therapy in a case of recurrent bladder cancer with multiple metastatic lesions","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib7-20241203","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-022-06048-5","article-title":"[177Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases","volume":"50","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20241203","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/RLU.0000000000005168","article-title":"177Lu-FAP-2286 therapy in a metastatic bone malignant solitary fibrous tumor","volume":"49","year":"2024","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T23:00:22Z","timestamp":1733266822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005489","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}